JP Morgan Chase’s Annovis Bio ANVS Stock Holding History

JP Morgan Chase’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.3K	Buy	15,219 +319	+2%	+$620	﹤0.01%	6630
2026 Q1	$29.9K	Hold	14,900	–	–	﹤0.01%	6394
2025 Q4	$51.6K	Hold	14,900	–	–	﹤0.01%	6211
2025 Q3	$30.8K	Hold	14,900	–	–	﹤0.01%	6378
2025 Q2	$32.3K	Buy	14,900 +6,100	+69%	+$12K	﹤0.01%	6055
2025 Q1	$13.2K	Buy	8,800 +5,000	+132%	+$15.3K	﹤0.01%	6248
2024 Q4	$19.1K	Hold	3,800	–	–	﹤0.01%	6260
2024 Q3	$30.6K	Buy	+3,800	New	+$35.6K	﹤0.01%	6139
2024 Q1	–	Sell	-152	Closed	-$2.84K	–	7380
2023 Q4	$2.84K	Buy	+152	New	+$1.35K	﹤0.01%	6667
2021 Q3	–	Sell	-8,024	Closed	-$687K	–	6458
2021 Q2	$687K	Buy	+8,024	New	+$371K	﹤0.01%	4514

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

JP Morgan Chase's ANVS Position: Q2 2026 in Review

JP Morgan Chase increased its Annovis Bio (ANVS) stake by 2.1% in Q2 2026, buying an estimated $620 and bringing the position to 15,219 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6630.

JP Morgan Chase first reported a position in ANVS in Q2 2021 and has held it in 10 quarters since. The position peaked at $687K in Q2 2021. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

JP Morgan Chase held 15,219 shares of Annovis Bio worth $28.3K as of Q2 2026.
JP Morgan Chase bought 319 Annovis Bio shares in Q2 2026, an estimated $620.
Annovis Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6630 holding.
JP Morgan Chase first reported a position in Annovis Bio in Q2 2021 and has held it in 10 quarters since.
JP Morgan Chase's Annovis Bio position peaked at $687K in Q2 2021.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.